Effect of Amlodipine/Nebivolol combination therapy on central BP and PWV compared to Amlodipine/Valsartan combination therapy.
Amlodipine/Nebivolol
Amlodipine/Valsartan
Arterial stiffness
Central blood pressure
Combination therapy
Hypertension
Journal
The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology
ISSN: 2090-911X
Titre abrégé: Egypt Heart J
Pays: Germany
ID NLM: 9106952
Informations de publication
Date de publication:
14 Mar 2022
14 Mar 2022
Historique:
received:
24
08
2021
accepted:
03
03
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
15
3
2022
Statut:
epublish
Résumé
Pulse wave velocity (PWV) and central blood pressure (CBP) have been intoduced into managment of hypertensive patients. PWV is positively correlated with arterial wall stiffness while central aortic pressure becomes better predictor of cardiovascular outcome than peripheral pressure. Reduction in CBP provides protective properties against subclinical organ damage. This work aims to investigate the effect of a new combination therapy of Amlodipine/Nebivolol (A/N) on central BP, peripheral BP and PWV. The results of using this combination will be compared to the well-established fixed-dose combination of Amlodipine/Valsartan (A/V). The study conducted between October 2018 and August 2020. One hundred and two hypertensive patients were assigned for Amlodipine 10 mg/Valsartan 160 mg combination therapy (A/V, n = 52) or Amlodipine 10 mg/Nebivolol 5 mg combination therapy (A/N, n = 50) by simple 1:1 randomization. Office, central blood pressure and PWV were measured on first (0 week), second (4-8 weeks) and third visit (10-12). Difference in BP (in each arm and between arms) was calculated along all visits. No statistical significant difference was found between A/V and A/N regarding age, gender, BMI and CV history. OBP, CBP and PWV were significantly reduced in each arm, but no differences were found when comparing both arm results to each other. Recorded side effects were insignificant. The new combination therapy Amlodipine/Nebivolol (A/N) affords a significant reduction in CBP, PBP and PWV with minor and tolerable side effects. It has provided comparable results to Amlodipine/Valsartan (A/V) combination therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Pulse wave velocity (PWV) and central blood pressure (CBP) have been intoduced into managment of hypertensive patients. PWV is positively correlated with arterial wall stiffness while central aortic pressure becomes better predictor of cardiovascular outcome than peripheral pressure. Reduction in CBP provides protective properties against subclinical organ damage. This work aims to investigate the effect of a new combination therapy of Amlodipine/Nebivolol (A/N) on central BP, peripheral BP and PWV. The results of using this combination will be compared to the well-established fixed-dose combination of Amlodipine/Valsartan (A/V). The study conducted between October 2018 and August 2020. One hundred and two hypertensive patients were assigned for Amlodipine 10 mg/Valsartan 160 mg combination therapy (A/V, n = 52) or Amlodipine 10 mg/Nebivolol 5 mg combination therapy (A/N, n = 50) by simple 1:1 randomization. Office, central blood pressure and PWV were measured on first (0 week), second (4-8 weeks) and third visit (10-12). Difference in BP (in each arm and between arms) was calculated along all visits.
RESULTS
RESULTS
No statistical significant difference was found between A/V and A/N regarding age, gender, BMI and CV history. OBP, CBP and PWV were significantly reduced in each arm, but no differences were found when comparing both arm results to each other. Recorded side effects were insignificant.
CONCLUSIONS
CONCLUSIONS
The new combination therapy Amlodipine/Nebivolol (A/N) affords a significant reduction in CBP, PBP and PWV with minor and tolerable side effects. It has provided comparable results to Amlodipine/Valsartan (A/V) combination therapy.
Identifiants
pubmed: 35286492
doi: 10.1186/s43044-022-00254-0
pii: 10.1186/s43044-022-00254-0
pmc: PMC8921398
doi:
Types de publication
Journal Article
Langues
eng
Pagination
15Informations de copyright
© 2022. The Author(s).
Références
J Clin Hypertens (Greenwich). 2020 Mar;22(3):391-406
pubmed: 31841279
Hypertens Res. 2010 May;33(5):398-410
pubmed: 20379189
Hypertension. 2003 Jan;41(1):183-7
pubmed: 12511550
QJM. 1999 Oct;92(10):595-600
pubmed: 10627881
Cardiol Rev. 2012 Sep-Oct;20(5):259-63
pubmed: 22573107
Hypertension. 2011 Jun;57(6):1122-8
pubmed: 21536983
J Hum Hypertens. 2006 Oct;20(10):787-94
pubmed: 16810279
Curr Pharm Des. 2009;15(3):272-89
pubmed: 19149618
J Clin Hypertens (Greenwich). 2020 Nov;22(11):1960-1967
pubmed: 32986936
Hypertension. 2009 Oct;54(4):724-30
pubmed: 19704107
Am J Hypertens. 2004 Feb;17(2):118-23
pubmed: 14751652
Diagnostics (Basel). 2021 Feb 03;11(2):
pubmed: 33546474
Vasc Health Risk Manag. 2011;7:777-87
pubmed: 22241952
Eur Heart J. 2006 Nov;27(21):2588-605
pubmed: 17000623
Am J Hypertens. 2006 Feb;19(2):214-9
pubmed: 16448896
Am J Hypertens. 2003 Nov;16(11 Pt 1):959-65
pubmed: 14573335
J Clin Hypertens (Greenwich). 2019 Sep;21(9):1386-1392
pubmed: 31465154
Obesity (Silver Spring). 2010 Dec;18(12):2311-6
pubmed: 20360756
J Clin Hypertens (Greenwich). 2013 Dec;15(12):910-7
pubmed: 24119182
Am J Med Sci. 2017 Jan;353(1):6-11
pubmed: 28104105
Stroke. 2001 Feb;32(2):454-60
pubmed: 11157182
PLoS One. 2017 Mar 2;12(3):e0173177
pubmed: 28253335
Int J Cardiol. 2017 Mar 1;230:209-213
pubmed: 28043670
Hypertension. 2007 Jul;50(1):154-60
pubmed: 17562972
J Clin Hypertens (Greenwich). 2018 Feb;20(2):258-265
pubmed: 29267992
Biomed Res Int. 2014;2014:621437
pubmed: 25170513
J Hypertens. 2018 Dec;36(12):2284-2309
pubmed: 30379783
Diabet Med. 2010 Dec;27(12):1430-5
pubmed: 21059096
J Clin Hypertens (Greenwich). 2017 Dec;19(12):1269-1275
pubmed: 29067767
J Hypertens. 2002 Apr;20(4):771-7
pubmed: 11910315
Hypertens Res. 2004 Nov;27(11):851-7
pubmed: 15824467